ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1292

Abnormal High Density Lipoprotein Particle Size and Number in Idiopathic Inflammatory Myopathies

Sangmee Bae1, Ilana Golub 2, Ani Shahbazian 3, Jennifer Wang 3 and Christina Charles-Schoeman 4, 1UCLA, Los Angeles, CA, 2UCLA, Los Angeles, 3UCLA Medical Center, Los Angeles, 4University of California, Los Angeles, CA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: lipids and Idiopathic Inflammatory Myopathies (IIM), Myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Muscle Biology, Myositis & Myopathies Poster II

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Vascular inflammation and damage are implicated in the pathogenesis of idiopathic inflammatory myopathies (IIM), particularly dermatomyositis (DM). High and low density lipoprotein (HDL, LDL) particles strongly influence the vascular endothelium, but little data has characterized these particles in IIM patients. The current work evaluates standard cholesterol levels as well as the particle number and size of HDL, LDL and very low density lipoproteins (VLDL) in IIM patients compared to healthy controls.

Methods: In a cross sectional analysis of 87 patients with IIM and 47 healthy controls (HC), we measured the quantitative lipoprotein profile by nuclear magnetic resonance spectroscopy (NMR). Cardiovascular risk factors and medications were obtained by questionnaire/chart review, and inflammatory markers and autoantibodies (ab) were measured by standard methods. Myositis disease activity was assessed using physician global 100 mm visual analogue scales (VAS) and CPK levels.

Results: The majority of patients in the IIM group had DM with a mean disease duration of 5 years and moderate disease activity (Table 1). Traditional fasting cholesterol levels were generally similar between patients with IIM and HC with mildly elevated triglycerides in the IIM group. Multiple differences in particular size and number including higher LDL particle number (LDL-P), larger HDL and VLDL size, and lower HDL particle number (HDL-P) were noted between IIM patients and HC. Multivariate (MV) models adjusted for demographics, factors known to affect lipid particle size/number (hypertension, diabetes, body mass index, statin use) and variables different in univariate comparison (ESR), were constructed for each significant lipid variable in table 1. Larger HDL size was strongly associated with IIM diagnosis, and smaller HDL-P was associated with disease activity in MV models. Triglycerides, LDL-P number and VLDL size were no longer associated with IIM diagnosis or disease activity in MV analysis. Patients with p155/140 ab had significantly larger HDL size, and patients with MDA5 ab had significantly lower HDL-P compared to patients without ab.

Conclusion: In a cross sectional analysis of IIM patients and healthy controls, larger HDL size was strongly associated with IIM diagnosis, and lower HDL-P was associated with higher physician global disease activity by VAS. Altered HDL size and particle number have previously been associated with vascular risk, and further work is needed to evaluate their role in vascular damage in patients with IIM.

IMAGE UNAVAILABLE

Mean-SD- unless specified, T test or Wilcoxon rank sum test for continuous variables, chi-square test or Fisher’s exact test for categorical variables, *ab data available in 61 IIM patients

IMAGE UNAVAILABLE

N=78 IIM patients with physician global disease activity VAS available


LipoprofileTable 3

>


Disclosure: S. Bae, None; I. Golub, None; A. Shahbazian, None; J. Wang, None; C. Charles-Schoeman, Abbvie, 2, AbbVie, 2, Amgen, 5, BMS, 2, Bristol Myers Squibb, 2, Gilead, 5, Octapharma, 2, 5, Pfizer, 2, 5, Regeneron, 5, Regeneron/Sanofi, 5, Sanofi, 5.

To cite this abstract in AMA style:

Bae S, Golub I, Shahbazian A, Wang J, Charles-Schoeman C. Abnormal High Density Lipoprotein Particle Size and Number in Idiopathic Inflammatory Myopathies [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/abnormal-high-density-lipoprotein-particle-size-and-number-in-idiopathic-inflammatory-myopathies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/abnormal-high-density-lipoprotein-particle-size-and-number-in-idiopathic-inflammatory-myopathies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology